FDA Flags Edwards Heart-Valve Delivery System After Patient Death, Injury
EW sits 22% above its 52-week low of $72.4.
Summary
The FDA warned Thursday of a potentially high-risk issue with certain Edwards delivery systems used in transcatheter mitral valve replacement, following one patient death and one serious injury. Edwards has asked customers to pull the affected devices from use and return impacted product. This is a safety action on a specific delivery system, not a broad recall of the company's core heart-valve franchise, but it lands on a company already carrying headline risk. Edwards just won FDA approval for AUTUS, its pediatric surgical pulmonary valve, on October 1, so the regulatory news flow has been mixed. The key question is scope: how many patients are affected, whether procedures are paused, and whether this expands into a formal recall or Class I designation.
At the time of this announcement, EW was trading at $88.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $50.8B. The 52-week trading range was $72.40 to $96.29. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.